The generic drug manufacturing company from India, Sun Pharmaceutical Industries Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to sell a generic version of AstraZeneca’s prostate cancer drug Casodex.
Casodex (bicalutamide) is an anti-androgen that block the ability of androgens (testosterone) to access the prostate cancer cell and “fuel” them. Used in combination with other drugs, Casodex forms one of the vital legs of androgen deprivation therapy (ADT) used to treat prostate cancer, including advance prostate cancer.
Having available a generic version of Casodex will save money for already overburdened prostate cancer survivors. Don’t forget to ask your doctor if the generic version of Casodex might be right for you.
Joel T Nowak MA, MSW